Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Semaglutide, the drug sold as Ozempic to treat type 2 diabetes and Wegovy for weight loss, reduced alcohol cravings and ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...